

**9 June 2021**

## ASX Announcement

### **ASEAN Dengue Day: Investor briefing notification**

MELBOURNE Australia, 9 June 2021: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to invite investors to a briefing on Tuesday 15 June 2021 to coincide with ASEAN Dengue Day.

Through the online briefing, CEO and Managing Director Dr David Foster, Executive Chairman Dr Paul MacLeman, and Infectious Disease expert Prof Stephen Thomas MD will discuss the most current understanding of the impact of dengue fever on the global community, the pace of growth in the ASEAN region and the changing battle against dengue in light of climate change and COVID-19.

CEO of Island Pharmaceuticals, Dr David Foster commented, "This briefing is an opportunity for Island to provide investors with a comprehensive sweep of the dengue landscape – covering impact of the disease on patients, recent research, delivered by industry experts."

#### **Topics to be covered in the session:**

- The global progress in addressing the unmet need
- Global weather patterns and the impact on the spread of disease
- Next steps in fighting mosquito borne viruses
- The briefing will be followed by a question-and-answer session

#### **Session info**

**Date:** Tuesday the 15 June 2021

**Time:** 10.30 am till 11.15 am AEST

**Online:** Zoom webinar platform – register to attend  
[https://us02web.zoom.us/webinar/register/WN\\_LohPQEdFOa2EP5qFzPnoZg](https://us02web.zoom.us/webinar/register/WN_LohPQEdFOa2EP5qFzPnoZg)

**RSVP:** Monday 14 June 2021

#### **Approved for release to the ASX by:**

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)



For further information, please contact:

<b>Investors:</b> Jane Lowe IR Department Mobile: +61 411 117 774 <a href="mailto:jane.lowe@irdepartment.com.au">jane.lowe@irdepartment.com.au</a>	<b>Media:</b> Juliana Roadley IR Department Mobile: +61 414 889 863 <a href="mailto:juliana.roadley@irdepartment.com.au">juliana.roadley@irdepartment.com.au</a>
--	--

### **About Island Pharmaceuticals**

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Isla may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) will permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market. Recent transactional benchmarking suggests that PRVs attract US\$75m-\$150m.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.